절제 기술 시장 예측(-2029년) : 기술별, 제품별, 용도별, 최종사용자별, 지역별

The global ablation technology market is projected to reach USD 9.62 billion by 2029 from USD 6.11 billion in 2024, at a CAGR of 9.5% from 2024 to 2029. Increasing risk for targeted diseases, supportive regulatory standards, and strategic partnerships and collaborations have driven demand for ablation technology market.

"The radiofrequency ablation segment of technology segment held the largest share of the market in 2023"

The ablation technology market is segmented based on technology into radiofrequency ablation, laser/light ablation, ultrasound ablation, electrical ablation, cryoablation, microwave ablation, pulsed field ablation and hydrothermal/hydromechanical ablation. Increasing demand for cardiac and tumor ablation procedures, growing awareness for early diagnosis, and technological advancements contributes to the largest share for this segment.

"The consumable segment of product segment held the largest share of the market in 2023"

The ablation technology market is segmented based on product into systems and consumables. Large share of consumables segment is supported by rising adoption of ablation systems in the end user facilities. Consumables need to be replaced for each procedure ensuring the patient safety. Extended application areas such as aesthetics, pain management, recent technological advancements, and strict regulatory policies to ensuring patient safety contribute to the highest share of the segment.

"The cardiovascular disease treatment segment for application segment held the largest share of the market in 2023".

Based on application, the ablation technology market is segmented by application into cardiovascular disease treatment, cancer treatment, orthopedic treatment, cosmetic/aesthetic treatment, urological treatment, gynecological treatment, pain management, ophthalmological treatment and other applications. Cardiovascular disease treatment segment held largest share of the segment in 2023. Improved success rate of ablation treatment for CVD and emerging technologies in ablation drives the segment growth.

"The Ambulatory surgery centers segment for the end user segment is projected to register a significant CAGR during the forecast period."

The ablation technology market is segmented by end user into hospitals, surgical centers and ablation centers, ambulatory surgery centers, medical spas and aesthetic clinics & dermatology clinics, and other end users. The hospitals, surgical centers and ablation centers segment accounted for a significant market share in 2023. Improved insurance coverage and an increase in outpatient treatments are two major factors driving the expansion of the ambulatory surgery center segment.

"The market in the Asia pacific region is expected to witness the highest growth during the forecast period."

Consistent rise in investment for healthcare services and infrastructure, especially in emerging economies, supports the rising installation of ablation systems. Key players in the market are focusing on expanding their presence in emerging countries to cater the increasing demand for ablation procedures. Moreover, the increasing number of hospitals, particularly in APAC region, increases the availability and accessibility of advanced treatment procedures, further driving the demand for ablation systems and consumables.

A breakdown of the primary participants referred to for this report is provided below:

• By Company Type: Tier 1-30%, Tier 2-42%, and Tier 3- 28%
• By Designation: Director-level-10%, C-level-14%, and Others-76%
• By Region: North America-40%, Europe-30%, Asia Pacific-22%, Latin America-6%, and the Middle East & Africa-2%

The prominent players in the ablation technology market Johnson & Johnson (US), Medtronic (US), Boston Scientific Corporation (US), Abbott (US), Atricure, Inc. (US), AngioDynamics (US), CONMED corporation (US), Olympus (Japan) among others.

Research Coverage

This report studies the ablation technology market based on technology, product, application, end user, and region. It also covers the factors affecting market growth, analyzes the various opportunities and challenges in the market, and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micro markets with respect to their growth trends and forecasts the revenue of the market segments with respect to five main regions (and the respective countries in these regions.

Reasons to Buy the Report

The report will help the market leaders/new entrants with information on the closest approximations of the revenue numbers for the overall ablation technology market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and plan suitable go-to-market strategies. The report also helps stakeholders understand the market pulse and provides information on key market drivers, restraints, challenges, and opportunities.

This report provides insights on the following pointers:

• Analysis of key drivers (Emerging technologies in the field of ablation, increasing demand for minimally invasive procedures, favorable reimbursement scenario in developed markets, and growing target patient population), restraints (presence of strong alternative therapies, stringent regulatory system), opportunities (growth potential in emerging countries), and challenges (focus on reuse and reprocessing of devices, therapeutic challenges and hazardous effects of ablation) influencing the growth of the ablation technology market
• Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product & service launches in the ablation technology market
• Market Development: Comprehensive information about lucrative markets-the report analyses the ablation technology market across varied regions.
• Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the ablation technology market
• Competitive Assessment: In-depth assessment of market shares, growth strategies, and service offerings of leading players - such as Johnson & Johnson (US), Medtronic (US), Boston Scientific Corporation (US), Abbott (US), Atricure, Inc. (US), AngioDynamics (US), CONMED corporation (US), Olympus (Japan) among others.

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
• 1.3 INCLUSIONS AND EXCLUSIONS
• 1.4 STUDY SCOPE
  • 1.4.1 SEGMENTS CONSIDERED
  • 1.4.2 YEARS CONSIDERED
  • 1.4.3 CURRENCY CONSIDERED
• 1.5 STAKEHOLDERS
• 1.6 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

• 2.1 RESEARCH DATA
  • 2.1.1 SECONDARY DATA
    • 2.1.1.1 Key secondary sources
    • 2.1.1.2 Objectives of secondary research
  • 2.1.2 PRIMARY DATA
    • 2.1.2.1 Key primary sources
    • 2.1.2.2 Objectives of primary research
    • 2.1.2.3 Key primary insights
    • 2.1.2.4 Breakdown of primaries
• 2.2 MARKET SIZE ESTIMATION
  • 2.2.1 BOTTOM-UP APPROACH
    • 2.2.1.1 Company revenue estimation approach
    • 2.2.1.2 Customer-based market estimation
    • 2.2.1.3 Growth forecast
    • 2.2.1.4 CAGR projections
• 2.3 DATA TRIANGULATION
• 2.4 RESEARCH LIMITATIONS
• 2.5 MARKET SHARE ANALYSIS
• 2.6 STUDY ASSUMPTIONS
• 2.7 GROWTH RATE ASSUMPTIONS
• 2.8 RISK ASSESSMENT

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

• 4.1 ABLATION TECHNOLOGY MARKET OVERVIEW
• 4.2 NORTH AMERICA: ABLATION TECHNOLOGY MARKET, BY TECHNOLOGY, 2024 VS. 2029 (USD MILLION)
• 4.3 ASIA PACIFIC: ABLATION TECHNOLOGY MARKET, BY END USER, 2024 VS. 2029 (USD MILLION)
• 4.4 EUROPE: ABLATION TECHNOLOGY MARKET, BY APPLICATION, 2024 VS. 2029 (USD MILLION)
• 4.5 GEOGRAPHIC SNAPSHOT OF ABLATION TECHNOLOGY MARKET

5 MARKET OVERVIEW

• 5.1 INTRODUCTION
• 5.2 MARKET DYNAMICS
  • 5.2.1 DRIVERS
    • 5.2.1.1 Emerging ablation technologies
    • 5.2.1.2 Increasing demand for minimally invasive procedures
    • 5.2.1.3 Growing target patient population
      • 5.2.1.3.1 Rapid growth in geriatric population with higher risk of targeted diseases
      • 5.2.1.3.2 Increasing incidence of cancer and sports injuries
      • 5.2.1.3.3 Rising prevalence of atrial fibrillation and other cardiovascular diseases
    • 5.2.1.4 Favorable reimbursement scenario in developed markets
  • 5.2.2 RESTRAINTS
    • 5.2.2.1 Strong market positioning of alternative therapies
    • 5.2.2.2 Stringent regulatory systems
  • 5.2.3 OPPORTUNITIES
    • 5.2.3.1 Growth potential in emerging economies
  • 5.2.4 CHALLENGES
    • 5.2.4.1 Focus on reuse and reprocessing of devices
    • 5.2.4.2 Therapeutic challenges and hazardous effects of ablation
• 5.3 VALUE CHAIN ANALYSIS
  • 5.3.1 RESEARCH & PRODUCT DEVELOPMENT
  • 5.3.2 RAW MATERIAL PROCUREMENT AND MANUFACTURING
  • 5.3.3 DISTRIBUTION, MARKETING & SALES, AND POST-SALES SERVICES
• 5.4 SUPPLY CHAIN ANALYSIS
  • 5.4.1 MANUFACTURERS
    • 5.4.1.1 Prominent companies
    • 5.4.1.2 Small and medium-sized enterprises
  • 5.4.2 END USERS
• 5.5 ECOSYSTEM ANALYSIS
• 5.6 REGULATORY LANDSCAPE
  • 5.6.1 REGULATORY ANALYSIS
    • 5.6.1.1 North America
      • 5.6.1.1.1 US
      • 5.6.1.1.2 Canada
    • 5.6.1.2 Europe
    • 5.6.1.3 Asia Pacific
      • 5.6.1.3.1 Japan
      • 5.6.1.3.2 China
      • 5.6.1.3.3 India
    • 5.6.1.4 Latin America
      • 5.6.1.4.1 Brazil
  • 5.6.2 REGULATORY APPROVALS
  • 5.6.3 KEY REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • 5.6.3.1 North America
    • 5.6.3.2 Europe
    • 5.6.3.3 Asia Pacific
    • 5.6.3.4 Latin America
    • 5.6.3.5 Middle East & Africa
• 5.7 REIMBURSEMENT SCENARIO ANALYSIS
• 5.8 INVESTMENT AND FUNDING SCENARIO
• 5.9 PRICING ANALYSIS
• 5.10 TRADE ANALYSIS
  • 5.10.1 IMPORT DATA FOR ABLATION PRODUCTS (HS CODE 9018)
  • 5.10.2 EXPORT DATA FOR ABLATION PRODUCTS (HS CODE 9018)
• 5.11 PATENT ANALYSIS
  • 5.11.1 TOP PATENT OWNERS/APPLICANTS
  • 5.11.2 LIST OF MAJOR PATENTS
• 5.12 PORTER'S FIVE FORCES ANALYSIS
  • 5.12.1 THREAT OF NEW ENTRANTS
  • 5.12.2 THREAT OF SUBSTITUTES
  • 5.12.3 BARGAINING POWER OF SUPPLIERS
  • 5.12.4 BARGAINING POWER OF BUYERS
  • 5.12.5 INTENSITY OF COMPETITIVE RIVALRY
• 5.13 KEY STAKEHOLDERS AND BUYING CRITERIA
  • 5.13.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • 5.13.2 KEY BUYING CRITERIA
• 5.14 KEY CONFERENCES AND EVENTS, 2024-2025
• 5.15 CASE STUDY ANALYSIS
  • 5.15.1 RADIOFREQUENCY ABLATION ANALYSIS CASE STUDY
  • 5.15.2 THERMOCOOL CATHETER CASE STUDY
• 5.16 TECHNOLOGY ANALYSIS
  • 5.16.1 KEY TECHNOLOGIES
    • 5.16.1.1 Thermal ablation technology
    • 5.16.1.2 Non-thermal ablation technology
  • 5.16.2 COMPLEMENTARY TECHNOLOGIES
    • 5.16.2.1 Medical cooling systems
  • 5.16.3 ADJACENT TECHNOLOGIES
    • 5.16.3.1 Ablation planning software
• 5.17 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
• 5.18 UNMET NEEDS
• 5.19 IMPACT OF AI/GEN AI ON ABLATION TECHNOLOGY MARKET
  • 5.19.1 KEY USE CASES

6 ABLATION TECHNOLOGY MARKET, BY TECHNOLOGY

• 6.1 INTRODUCTION
• 6.2 RADIOFREQUENCY ABLATION
  • 6.2.1 LOWER COST AND HIGHER EFFICACY TO PROPEL MARKET GROWTH
• 6.3 LASER/LIGHT ABLATION
  • 6.3.1 LOWER RISK OF TISSUE DAMAGE AND BETTER REAL-TIME MONITORING TO AID MARKET GROWTH
• 6.4 ULTRASOUND ABLATION
  • 6.4.1 HIGH INCIDENCE OF LIVER TUMORS AND CANCER TO FUEL MARKET GROWTH
• 6.5 ELECTRICAL ABLATION
  • 6.5.1 INCREASING NUMBER OF CARDIAC ARRESTS TO BOOST ADOPTION
• 6.6 CRYOABLATION
  • 6.6.1 FEWER COMPLICATIONS AND SHORTER PROCEDURAL TIME TO DRIVE MARKET
• 6.7 MICROWAVE ABLATION
  • 6.7.1 FASTER ABLATION TIME AND LESSER PROCEDURAL PAIN TO AUGMENT MARKET GROWTH
• 6.8 PULSED-FIELD ABLATION
  • 6.8.1 IMPROVED SAFETY, SHORTER PROCEDURAL TIME, AND FEWER COMPLICATIONS TO PROPEL MARKET GROWTH
• 6.9 HYDROTHERMAL/HYDROMECHANICAL ABLATION
  • 6.9.1 INCREASED USAGE IN GYNECOLOGICAL DISORDERS AND MENORRHAGIA TO AID MARKET GROWTH

7 ABLATION TECHNOLOGY MARKET, BY PRODUCT

• 7.1 INTRODUCTION
• 7.2 RADIOFREQUENCY ABLATION SYSTEMS
  • 7.2.1 TEMPERATURE-CONTROLLED RADIOFREQUENCY ABLATION SYSTEMS
    • 7.2.1.1 Technological advancements and improved clinical outcomes to propel segment growth
  • 7.2.2 FLUID-COOLED RADIOFREQUENCY ABLATION SYSTEMS
    • 7.2.2.1 Rising incidence of arrhythmia and growing focus on reducing collateral tissue damage to boost demand
  • 7.2.3 ROBOTIC CATHETER MANIPULATION SYSTEMS
    • 7.2.3.1 Manual control of catheter movement and remote navigation to fuel segment
• 7.3 LASER/LIGHT ABLATION SYSTEMS
  • 7.3.1 EXCIMER LASER ABLATION SYSTEMS
    • 7.3.1.1 Low direct tissue interaction, precise ablation zone, and high procedural efficiency to drive adoption
  • 7.3.2 COLD LASER ABLATION SYSTEMS
    • 7.3.2.1 Cold laser ablator treatment to release endorphins and support pain management
• 7.4 ULTRASOUND ABLATION SYSTEMS
  • 7.4.1 ULTRASONIC SURGICAL ABLATION SYSTEMS
    • 7.4.1.1 Development of user-friendly surgical ablation systems to drive segment growth
  • 7.4.2 HIGH-INTENSITY FOCUSED ULTRASOUND ABLATION SYSTEMS
    • 7.4.2.1 Low procedural time and reduced bleeding to support system adoption
  • 7.4.3 EXTRACORPOREAL SHOCK WAVE LITHOTRIPSY SYSTEMS
    • 7.4.3.1 Growing incidence of obesity and diabetes to drive segment
  • 7.4.4 MAGNETIC RESONANCE-GUIDED FOCUSED ULTRASOUND ABLATION SYSTEMS
    • 7.4.4.1 Non-pregnancy safe treatment procedure to limit adoption
• 7.5 ELECTRICAL ABLATION SYSTEMS
  • 7.5.1 ARGON PLASMA/BEAM COAGULATION SYSTEMS
    • 7.5.1.1 Increased focus on treating Barrett's esophagus without dysplasia to augment segment growth
  • 7.5.2 IRREVERSIBLE ELECTROPORATION ABLATION SYSTEMS
    • 7.5.2.1 Selective targeting and better control to aid segment growth
• 7.6 CRYOABLATION SYSTEMS
  • 7.6.1 TECHNOLOGICAL ADVANCEMENTS AND INTRODUCTION OF NEW CRYOPROBES TO AID ADOPTION
  • 7.6.2 EPIDERMAL AND SUBCUTANEOUS CRYOABLATION DEVICES
• 7.7 MICROWAVE ABLATION SYSTEMS
  • 7.7.1 PRODUCTION OF LARGE ABLATION ZONES WITHOUT HEAT-SINK EFFECT ON SURROUNDING TISSUES TO DRIVE MARKET
  • 7.7.2 MICROWAVE THERMOTHERAPY SYSTEMS
• 7.8 HYDROTHERMAL/HYDROMECHANICAL ABLATION SYSTEMS
  • 7.8.1 INCREASED NEED FOR MINIMALLY INVASIVE PROCEDURES FOR GYNECOLOGICAL DISORDERS TO SUPPORT MARKET GROWTH
  • 7.8.2 ENDOMETRIAL HYDROTHERMAL BALLOON ABLATION DEVICES
• 7.9 CONSUMABLES
  • 7.9.1 GROWING PREFERENCE FOR ADVANCED MINIMALLY INVASIVE PROCEDURES TO SPUR MARKET GROWTH

8 ABLATION TECHNOLOGY MARKET, BY APPLICATION

• 8.1 INTRODUCTION
• 8.2 CARDIOVASCULAR DISEASE TREATMENT
  • 8.2.1 INCREASING TARGET PATIENT POPULATION TO PROPEL MARKET GROWTH
• 8.3 CANCER TREATMENT
  • 8.3.1 HIGH PREVALENCE OF CANCER AND NEED FOR ADVANCED TREATMENT PROCEDURES TO AUGMENT MARKET GROWTH
  • 8.3.2 LIVER CANCER
  • 8.3.3 KIDNEY CANCER
  • 8.3.4 PROSTATE CANCER
  • 8.3.5 LUNG CANCER
  • 8.3.6 BONE METASTASIS
  • 8.3.7 BREAST CANCER
• 8.4 ORTHOPEDIC TREATMENT
  • 8.4.1 GROWING DISEASE PREVALENCE AND RISING GERIATRIC POPULATION TO SPUR MARKET GROWTH
• 8.5 COSMETIC/AESTHETIC SURGERY
  • 8.5.1 INCREASING DEMAND FOR AESTHETIC SURGICAL PROCEDURES TO FUEL MARKET GROWTH
• 8.6 UROLOGICAL TREATMENT
  • 8.6.1 HIGH DEMAND FOR MINIMALLY INVASIVE PROCEDURES AMONG PATIENTS TO DRIVE MARKET
• 8.7 GYNECOLOGICAL TREATMENT
  • 8.7.1 INCREASING REPRODUCTIVE HEALTH CONCERNS AND DECREASING FERTILITY RATE TO PROPEL MARKET GROWTH
• 8.8 PAIN MANAGEMENT
  • 8.8.1 MINIMUM RECOVERY TIME AND LONG-LASTING PAIN RELIEF TO SUPPORT MARKET GROWTH
• 8.9 OPHTHALMOLOGICAL TREATMENT
  • 8.9.1 RISING PREVALENCE OF VISION DISORDERS AMONG ALL AGE GROUPS TO AID MARKET GROWTH
• 8.10 OTHER APPLICATIONS

9 ABLATION TECHNOLOGY MARKET, BY END USER

• 9.1 INTRODUCTION
• 9.2 HOSPITALS, SURGICAL CENTERS, AND ABLATION CENTERS
  • 9.2.1 HIGH ADOPTION OF ROBOTIC PROCEDURES IN SURGERIES AND IMPROVED HEALTHCARE INFRASTRUCTURE TO DRIVE MARKET
• 9.3 AMBULATORY SURGERY CENTERS
  • 9.3.1 NEED FOR COST-EFFECTIVE OUTPATIENT TREATMENTS TO SPUR MARKET GROWTH
• 9.4 MEDICAL SPAS AND AESTHETIC & DERMATOLOGY CLINICS
  • 9.4.1 INCREASING PREFERENCE FOR MINIMALLY INVASIVE AND NON-INVASIVE AESTHETIC PROCEDURES TO BOOST MARKET GROWTH
• 9.5 OTHER END USERS

10 ABLATION TECHNOLOGY MARKET, BY REGION

• 10.1 INTRODUCTION
• 10.2 NORTH AMERICA
  • 10.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
  • 10.2.2 US
    • 10.2.2.1 US to dominate North American ablation technology market during forecast period
  • 10.2.3 CANADA
    • 10.2.3.1 Rising burden of cancer and growing demand for minimally invasive procedures to support market growth
• 10.3 EUROPE
  • 10.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
  • 10.3.2 GERMANY
    • 10.3.2.1 Developed healthcare infrastructure and high incidence of chronic diseases to support market growth
  • 10.3.3 FRANCE
    • 10.3.3.1 Growing geriatric population and rising prevalence of cancer to aid market growth
  • 10.3.4 UK
    • 10.3.4.1 Rising target patient population and growing awareness about advanced treatment options to drive market
  • 10.3.5 ITALY
    • 10.3.5.1 Increasing number of clinical trials and growing focus on advanced research activities to augment market growth
  • 10.3.6 SPAIN
    • 10.3.6.1 Increasing government research funding and growing focus on effective cancer diagnosis to propel market growth
  • 10.3.7 REST OF EUROPE
• 10.4 ASIA PACIFIC
  • 10.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
  • 10.4.2 JAPAN
    • 10.4.2.1 Presence of universal healthcare reimbursement system to augment market growth
  • 10.4.3 CHINA
    • 10.4.3.1 Increased patient pool and favorable government initiatives to fuel market growth
  • 10.4.4 INDIA
    • 10.4.4.1 Modernization of healthcare infrastructure and increased medical tourism to aid market growth
  • 10.4.5 AUSTRALIA
    • 10.4.5.1 Increased research investments and favorable government initiatives to spur market growth
  • 10.4.6 SOUTH KOREA
    • 10.4.6.1 Focus on healthcare R&D and supportive government initiatives to positively impact market growth
  • 10.4.7 REST OF ASIA PACIFIC
• 10.5 LATIN AMERICA
  • 10.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
  • 10.5.2 BRAZIL
    • 10.5.2.1 Increasing government funding and growing burden of chronic diseases to propel market growth
  • 10.5.3 MEXICO
    • 10.5.3.1 Availability of advanced care initiatives and awareness programs to fuel market growth
  • 10.5.4 REST OF LATIN AMERICA
• 10.6 MIDDLE EAST & AFRICA
  • 10.6.1 IMPROVED HEALTHCARE INFRASTRUCTURE AND HIGH PUBLIC-PRIVATE INVESTMENTS TO STIMULATE MARKET GROWTH
  • 10.6.2 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA

11 COMPETITIVE LANDSCAPE

• 11.1 INTRODUCTION
• 11.2 KEY PLAYER STRATEGY/RIGHT TO WIN
  • 11.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN ABLATION TECHNOLOGY MARKET
• 11.3 REVENUE ANALYSIS, 2019-2023
• 11.4 MARKET SHARE ANALYSIS, 2023
• 11.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
  • 11.5.1 STARS
  • 11.5.2 EMERGING LEADERS
  • 11.5.3 PERVASIVE PLAYERS
  • 11.5.4 PARTICIPANTS
  • 11.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
    • 11.5.5.1 Company footprint
    • 11.5.5.2 Technology footprint
    • 11.5.5.3 Product footprint
    • 11.5.5.4 Application footprint
    • 11.5.5.5 End-user footprint
    • 11.5.5.6 Region footprint
• 11.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
  • 11.6.1 PROGRESSIVE COMPANIES
  • 11.6.2 RESPONSIVE COMPANIES
  • 11.6.3 DYNAMIC COMPANIES
  • 11.6.4 STARTING BLOCKS
  • 11.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
• 11.7 COMPANY VALUATION AND FINANCIAL METRICS
  • 11.7.1 FINANCIAL METRICS
  • 11.7.2 COMPANY VALUATION
• 11.8 BRAND/PRODUCT COMPARISON
• 11.9 COMPETITIVE SCENARIO
  • 11.9.1 PRODUCT LAUNCHES AND APPROVALS
  • 11.9.2 DEALS
  • 11.9.3 EXPANSIONS

12 COMPANY PROFILES

• 12.1 KEY PLAYERS
  • 12.1.1 JOHNSON & JOHNSON
    • 12.1.1.1 Business overview
    • 12.1.1.2 Products offered
    • 12.1.1.3 Recent developments
      • 12.1.1.3.1 Product approvals
      • 12.1.1.3.2 Deals
    • 12.1.1.4 MnM view
      • 12.1.1.4.1 Key strengths
      • 12.1.1.4.2 Strategic choices
      • 12.1.1.4.3 Weaknesses and competitive threats
  • 12.1.2 MEDTRONIC
    • 12.1.2.1 Business overview
    • 12.1.2.2 Products offered
    • 12.1.2.3 Recent developments
      • 12.1.2.3.1 Product approvals
    • 12.1.2.4 MnM view
      • 12.1.2.4.1 Key strengths
      • 12.1.2.4.2 Strategic choices
      • 12.1.2.4.3 Weaknesses and competitive threats
  • 12.1.3 BOSTON SCIENTIFIC CORPORATION
    • 12.1.3.1 Business overview
    • 12.1.3.2 Products offered
    • 12.1.3.3 Recent developments
      • 12.1.3.3.1 Product approvals
      • 12.1.3.3.2 Deals
    • 12.1.3.4 MnM view
      • 12.1.3.4.1 Key strengths
      • 12.1.3.4.2 Strategic choices made
      • 12.1.3.4.3 Weaknesses and competitive threats
  • 12.1.4 ABBOTT
    • 12.1.4.1 Business overview
    • 12.1.4.2 Products offered
    • 12.1.4.3 Recent developments
      • 12.1.4.3.1 Product approvals
      • 12.1.4.3.2 Deals
  • 12.1.5 ATRICURE, INC.
    • 12.1.5.1 Business overview
    • 12.1.5.2 Products offered
    • 12.1.5.3 Recent developments
      • 12.1.5.3.1 Product launches and approvals
  • 12.1.6 ANGIODYNAMICS
    • 12.1.6.1 Business overview
    • 12.1.6.2 Products offered
    • 12.1.6.3 Recent developments
      • 12.1.6.3.1 Deals
  • 12.1.7 CONMED CORPORATION
    • 12.1.7.1 Business overview
    • 12.1.7.2 Products offered
  • 12.1.8 OLYMPUS CORPORATION
    • 12.1.8.1 Products offered
    • 12.1.8.2 Recent developments
      • 12.1.8.2.1 Product launches
      • 12.1.8.2.2 Deals
  • 12.1.9 VARIAN MEDICAL SYSTEMS, INC.
    • 12.1.9.1 Business overview
    • 12.1.9.2 Products offered
    • 12.1.9.3 Recent developments
      • 12.1.9.3.1 Product launches
      • 12.1.9.3.2 Deals
  • 12.1.10 SMITH+NEPHEW
    • 12.1.10.1 Business overview
    • 12.1.10.2 Product offered
    • 12.1.10.3 Recent developments
      • 12.1.10.3.1 Expansions
  • 12.1.11 STRYKER
    • 12.1.11.1 Business overview
    • 12.1.11.2 Products offered
    • 12.1.11.3 Recent developments
      • 12.1.11.3.1 Product approvals
      • 12.1.11.3.2 Expansions
  • 12.1.12 CYNOSURE LUTRONIC
    • 12.1.12.1 Business overview
    • 12.1.12.2 Products offered
    • 12.1.12.3 Recent developments
      • 12.1.12.3.1 Deals
  • 12.1.13 BIOVENTUS
    • 12.1.13.1 Business overview
    • 12.1.13.2 Products offered
      • 12.1.13.2.1 Deals
  • 12.1.14 MERIT MEDICAL SYSTEMS
    • 12.1.14.1 Business overview
    • 12.1.14.2 Products offered
  • 12.1.15 CANYON MEDICAL INC.
    • 12.1.15.1 Business overview
    • 12.1.15.2 Products offered
• 12.2 OTHER PLAYERS
  • 12.2.1 ARTHREX, INC.
  • 12.2.2 ICECURE MEDICAL
  • 12.2.3 MINIMAX MEDICAL HOLDING GROUP
  • 12.2.4 CARDIOFOCUS
  • 12.2.5 EDAP TMS
  • 12.2.6 MERMAID MEDICAL
  • 12.2.7 MONTERIS
  • 12.2.8 SONABLATE CORP.
  • 12.2.9 ECO MEDICAL
  • 12.2.10 SURGNOVA

13 APPENDIX

• 13.1 DISCUSSION GUIDE
• 13.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 13.3 CUSTOMIZATION OPTIONS
• 13.4 RELATED REPORTS
• 13.5 AUTHOR DETAILS